

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number  
**WO 2005/092858 A3**(51) International Patent Classification<sup>7</sup>: **C07D 221/20**,  
491/10, 471/10, 471/06, 401/06(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., 201 Tabor  
Road, Morris Plains, NJ 07950 (US).(21) International Application Number:  
**PCT/IB2005/000751**(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW.

(22) International Filing Date: 16 March 2005 (16.03.2005)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:  
60/557,598 29 March 2004 (29.03.2004) US(71) Applicant (for JP only): **PFIZER JAPAN INC.** [JP/JP];  
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku.,  
Tokyo 151-8589 Japan (JP).(71) Applicant (for all designated States except JP, US):  
**PFIZER INC.** [US/US]; 235 East 42nd Street, New York,  
NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HASHIZUME**,  
Yoshinobu [JP/JP]; Pfizer Global Research and Develop-  
ment, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken  
470-2393 (JP). **HIROTA, Masako** [JP/JP]; Pfizer Global  
Research and Development, Nagoya, Pfizer Japan Inc.,  
2 Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken  
470-2393 (JP). **MIHARA, Sachiko** [JP/JP]; Pfizer Global  
Research and Development, 2, Aza 5-gochi, Taketoyo-cho,  
Chita-gun, Aichi-ken 470-2393 (JP). **NAKAMURA, Hi-**  
**roshi** [JP/JP]; Pfizer Global Research and Development,  
2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken  
470-2393 (JP). **KOIKE, Hiroki** [JP/JP]; Pfizer Global  
Research and development, Nagoya, Pfizer Japan Inc.,  
2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken  
470-2393 (JP). **MATSUMOTO, Yukari** [JP/JP]; Pfizer  
Global Research and development, Nagoya, Pfizer Japan  
Inc., 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken  
470-2393 (JP).(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
2 March 2006(48) Date of publication of this corrected version:  
20 April 2006(15) Information about Correction:  
see PCT Gazette No. 16/2006 of 20 April 2006For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.(54) Title: **ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RE-  
CEPTOR ANTAGONIST**

(I)

(57) Abstract: This invention provides the compounds  
of formula (I): or a pharmaceutically acceptable ester  
of such compound, or a pharmaceutically acceptable  
salt thereof, wherein R<sup>1</sup> and R<sup>2</sup> independently represent  
a hydrogen atom or the like; R<sup>3</sup> represents a hydrogen  
atom, or the like; R<sup>4</sup> represents a hydrogen atom or the  
like; (formula II) represents one of the following or the  
like; R<sup>5</sup> represents an aryl group having from 6 to 10 ring  
atoms or the like; X represents an oxygen atom, or thelike; Y represents an oxygen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist  
activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

WO 2005/092858 A3